ANI Pharmaceuticals, Inc.
ANIPHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, ANI Pharmaceuticals, Inc. (ANIP) is listed under Drug Manufacturers - Specialty & Generic. The $1.69B market capitalization puts ANIP squarely in small-cap range for its industry. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Market Cap
$1.69B
Beta
0.49
P/E (TTM)
16.10
P/E (Fwd)
7.25
EPS (TTM)
$4.58
EPS (Fwd)
$10.17
ROE
20.5%
ROA
5.5%
Cash
$377.0M
Total Debt
$626.0M
Free CF
$132.2M
52W Change
-22.3%
Annual Financials
Cash vs Debt
Where ANIP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ANIP finished 6.64% below its 150-day moving average ($77.72) and 6.99% below its 200-day moving average ($78.01). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANIP overbought or oversold?
At the October 20, 2026 close, ANIP's RSI(14) was 49.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $377.0M in cash, though total debt stands at $626.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $132.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 20.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $316.4M (2022) to $883.4M (2025), reflecting a 179% increase over the period.
The relatively low beta of 0.49 suggests ANIP is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ANIP.